Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo (cemiplimab-rwlc)
17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics
TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
"The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies. Poised to tackle more than 30 types of cancer, our oncology pipeline is a testament to Regeneron's relentless commitment to transforming cancer care for those who need it most."
Beyond the REGN7075 data, additional presentations will feature results from Regeneron's diverse pipeline of checkpoint inhibitors and bispecific antibodies. Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.
Regeneron presentations at ASCO:
| Medicine | Abstract title | Abstract | Lead author | Presentation date/time (all CDT) |
| Solid Tumor Malignancies | ||||
| REGN7075, Libtayo | A Phase 1/2 study of REGN7075 in combination with cemiplimab in patients with advanced solid tumors: Updated dose escalation results | #2503 Oral Presentation Session— Developmental Therapeutics—Immunotherapy | Segal, N.H. | Monday, June 3 11:30 a.m. – 2:30 p.m. |
| REGN6569, Libtayo | A Phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results | #2650 Poster Presentation Session— Developmental Therapeutics—Immunotherapy | Lakhani, N.J. | Saturday, June 1 9:00 a.m. – 12:00 p.m. |
| Blood Cancer | ||||
| Linvoseltamab | Indirect comparison of linvoseltamab (linvo) versus teclistamab (tec) for treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) | #7560 Poster Presentation Session— Hematologic Malignancies—Plasma Cell Dyscrasia | Jagannath, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Linvoseltamab | Comparative effectiveness of linvoseltamab (Linvo) vs. standard of care (SOC) in real-world patients (pts) with triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) | #7561 Poster Presentation Session— Hematologic Malignancies—Plasma Cell Dyscrasia | Kumar, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1) | #7096 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Birhiray, R. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2) | #7099 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Hardin, C. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3) | #7086 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Matasar, M. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL;OLYMPIA-4) | #7093 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Hawkes, E.A. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal one lymphoma (MZL; (OLYMPIA-5) | #7094 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Vitolo, U. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Results from the follicular lymphoma (FL) outcomes in relapsed/refractory (R/R) patients treated with systemic therapy in a real-world assessment (FLORA) study | #7076 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Luminari, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Skin Cancer | ||||
| Fianlimab, Libtayo | A Phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma | #TPS9611 Poster Presentation Session— Melanoma/Skin Cancers | Khushalani, N.I. | Saturday, June 1 1:30 p.m. – 4:30 p.m. |
| Lung Cancer | ||||
| Fianlimab, Libtayo | A Phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line advanced non-small cell lung cancer | #TPS8660 Poster Presentation Session— Lung Cancer—Non-Small Cell Metastatic | Gabrail, N. | Monday, June 3 1:30 p.m. – 4:30 p.m |
| Fianlimab, Libtayo | A Phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L ≥50% | #TPS8663 Poster Presentation Session— Lung Cancer—Non-Small Cell Metastatic | Faulkner, N. | Monday, June 3 1:30 p.m. – 4:30 p.m. |
| Gynecologic Cancer | ||||
| Libtayo | Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer* | #5522 Poster Presentation Session— Gynecologic Cancer | Lorusso, D. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Ubamatamab, Libtayo | A Phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update | #TPS5632 Poster Presentation Session— Gynecologic Cancer | Nieuwenhuysen, E. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Head and Neck Cancer | ||||
| Fianlimab, Libtayo | A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC | #6038 Poster Presentation Session— Head and Neck Cancer | Cho, B.C. | Sunday, June 2 9:00 a.m. – 12:00 p.m. |
| DB-020 | A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity | #6100 Poster Presentation Session— Head and Neck Cancer | Rischin, D. | Sunday, June 2 9:00 a.m. – 12:00 p.m. |
*Study conducted in collaboration between Regeneron and ISA.
The potential uses of Libtayo, REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 as described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 are not currently approved for use in any indication.